Tuesday 6 December 2016

Elan says Tysabri patient numbers disappointing

Trista Kelley

Published 21/04/2010 | 13:00

Elan’s Tysabri multiple sclerosis medicine attracted a disappointing number of new patients in the first three months of the year, Chief Executive Officer Kelly Martin said.

  • Go To

“The first quarter was not where we wanted to be in terms of net new patients,” Martin said in a phone interview today from New York.

“Adding 140 to 150 patients a week isn’t bad but when you look at the medical need we think it should be much higher than that.”

Elan’s first-quarter net loss narrowed to $2m from $102.6m a year earlier.

Ian Hunter, a Goodbody Stockbrokers analyst in Dublin, had estimated a loss of $25m for the Dublin company.

Doctors temporarily taking patients off the medicine may be hindering sales, Martin said.

“Doctors are taking patients off the drug for a few months,” he said. “We don’t have visibility for how those numbers will pan out.”

Total Tysabri sales increased 28pc to $292m in the first quarter, Elan said today. That missed Hunter’s sales estimate by 10pc.


Read More

Promoted articles

Editors Choice

Also in Business